secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2024-03-27T23:59:59+00:00
Accession:  0001437749-24-009476
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zevra reports positive Phase 2 top-line data for KP1077 in idiopathic hypersomnia
--------------------------------------------------------------------------------

- KP1077 showed clinically meaningful improvement in excessive daytime sleepiness on ESS, maintained through open-label and double-blind phases.
- Improvements also observed in IHSS, Sleep Inertia VAS, and Brain Fog severity scale at end of both open-label and double-blind periods.
- Drug was well-tolerated at all doses (up to 320 mg/day); most common AEs were insomnia, headache, anxiety, nausea, decreased appetite.
- Company plans to request end-of-Phase 2 meeting with FDA for guidance on Phase 3 trial design.
- Study enrolled 66 patients; 50 continued into double-blind phase; not powered for statistical significance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143774924009476/0001437749-24-009476-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143774924009476/zvra20240326_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-009476

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer